• Publications
  • Influence
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.
BACKGROUND We update recommendations on 12 topics that were in the 9th edition of these guidelines, and address 3 new topics. METHODS We generate strong (Grade 1) and weak (Grade 2) recommendationsExpand
  • 2,325
  • 144
  • Open Access
Oral rivaroxaban for symptomatic venous thromboembolism.
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without the need forExpand
  • 1,855
  • 67
  • Open Access
Prediction of Pulmonary Embolism in the Emergency Department: The Revised Geneva Score
Context Using clinical findings to estimate the probability of disease can help guide management decisions. Contribution These investigators used data from 2 independent studies to derive andExpand
  • 752
  • 28
  • Open Access
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
BackgroundStandard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct oral anticoagulants have been investigated for acute and extendedExpand
  • 403
  • 26
  • Open Access
Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score.
OBJECTIVE To develop a simple standardized clinical score to stratify emergency ward patients with clinically suspected pulmonary embolism (PE) into groups with a high, intermediate, or lowExpand
  • 537
  • 18
  • Open Access
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
BACKGROUND A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without theExpand
  • 1,479
  • 16
  • Open Access
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
BACKGROUND Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full‐ or lower‐intensity anticoagulation therapy or aspirin.Expand
  • 295
  • 14
  • Open Access
Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.
Reliable prediction of adverse outcomes in acute pulmonary embolism may help choose between in-hospital and ambulatory treatment. We aimed to identify predictors of adverse events in patients withExpand
  • 321
  • 12
D-dimer testing for suspected pulmonary embolism in outpatients.
The plasma level of D-dimer, a fibrin degradation product (FDP), is nearly always increased in the presence of acute pulmonary embolism (PE). Hence, a normal D-dimer level (below a cutoff value ofExpand
  • 235
  • 10
Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study.
IMPORTANCE D-dimer measurement is an important step in the diagnostic strategy of clinically suspected acute pulmonary embolism (PE), but its clinical usefulness is limited in elderly patients. Expand
  • 407
  • 8
  • Open Access